


WE CLAIM:

1. A compound of formula I:



I;

wherein:

R^1 and R^2 are each independently H, OH, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, CF_3 , halo or $NR^4R^{4'}$;

R^3 is H, C_1 - C_6 alkyl;

X is a 5 membered aromatic heterocycle that is optionally substituted with C_1 - C_4 alkyl; wherein said heterocycle contains at least two or three heteroatoms selected from N, S and O wherein at least one heteroatom must be N;

Y is S, $CR^5=N$ or $N=CR^5$;

n is 2, 3, 4, 5, 6 or 7;


R^4 is H, COR^6 , SO_2R^7 , or C_1 - C_6 alkyl;

$R^{4'}$ is H or C_1 - C_6 alkyl;

R^5 is H or forms a bond with X;

R^6 is H or C_1 - C_6 alkyl; and


R^7 is H or C_1 - C_6 alkyl; or a pharmaceutical salt thereof; wherein said compound of formula I is not:



2. The compound of claim 1 wherein R^1 and R^2 are each independently H, OH, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, CF_3 , halo or $NR^4R^{4'}$ and wherein X is not substituted with C_1 - C_4 alkyl.


3. The compound of claim 1 or 2 wherein R^3 is H.

4. The compound of any one of claims 1-3 wherein X is




; R^3 is H and the $(CH_2)_nCO_2R^3$ moiety is attached at position number 2; or a pharmaceutical salt thereof.

5. The compound of any one of claims 1-3 wherein X is




; R^3 is H and the $(CH_2)_nCO_2R^3$ moiety is attached at position number 5; or a pharmaceutical salt thereof.

6. A compound which is




or a pharmaceutical salt thereof.

7. A compound which is




or a pharmaceutical salt thereof.

8. A compound which is




or a pharmaceutical salt thereof.

9. A compound which is




or a pharmaceutical salt thereof.

10. A compound which is



or a pharmaceutical salt thereof.

11. A compound which is .



or a pharmaceutical salt thereof.

12. A pharmaceutical composition comprising:

- a) a compound of any one of claims 3-11 or a pharmaceutical salt thereof; and
- b) a GLP-1 compound.

13. The composition of claim 14 wherein the GLP-1 compound is Val⁸-Glu²²-GLP-1(7-37)OH.

14. A pharmaceutical composition comprising:
- a) a compound of any one of claims 3-11 or a pharmaceutical salt thereof; and
 - b) an MC4 agonist peptide.
15. The composition of claim 16 wherein the MC4 agonist peptide is selected from the group consisting of:
- Ac-Arg-cyclo[Cys-Glu-His-D-Phe-Arg-Trp-Cys]-NH₂;
- Ac-cyclo[hCys-His-D-Phe-Arg-Trp-Cys]-NH₂;
- Ac-cyclo[hCys-His-D-Phe-Arg-Trp-penicillamine]-NH₂; and
- N-cyclohexanecarbonyl-cyclo[hCys-His-D-Phe-Arg-Trp-penicillamine]-NH₂.